At the IGTP TODAY
A team of researchers including the GRENBA group at IGTP has identified a promising therapy based on antimiRs to treat myotonic dystrophy type 1 (DM1). The results of their research have just been published in Science Advances.
Researchers from Barcelona's Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results, published in the Journal of Clinical Investigation, builds on two harmonized Phase I clinical trials funded by the European Union, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The team is now preparing to move into Phase II trials to further explore these findings.
To keep weight in check, it is not only important to consider what we eat, but also the times at which we eat. According to a study published in the International Journal of Behavioral Nutrition and Physical Activity, there are two specific habits that are associated with a lower body mass index (BMI) in the long term: keeping a longer overnight fast and eating breakfast early. This research was led by ISGlobal and was carried out in collaboration with the GCAT cohort from IGTP.
Researchers from IGTP have analysed the regulatory B cells of patients who have undergone a kidney transplant, evaluating their potential as predictive markers of organ damage and rejection risk. The study, published in the journal Frontiers in Immunology, highlights the importance of studying the immune system in these cases and proposes new tools for clinical practice.
 (1)_1727087752.jpg)
A new study, published in New England Journal of Medicine, has demonstrated the benefits of placing a clip on the valve instead of the usual medical treatment. The study includes the participation of Professor Antoni Bayés-Genís, principal investigator of the ICREC group and Director of the Heart Institute at Germans Trias Hospital.
_1725960548.jpg)
IGTP leading the first study in the world to prove that personalised therapies are more effective than classic drugs indicated for the treatment of this rare hormonal disease. It is based on response biomarkers that, depending on what they indicate, allow the best possible treatment to be assigned earlier. In addition to very noticeable facial and skeletal deformities, acromegaly causes severe alterations in other parts of the body. Published in The Journal of Clinical Endocrinology & Metabolism.
_1723033241.jpg)
A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d’Oncologia (ICO) analysed peripheral blood samples from patients with metastatic colorectal cancer and identified a potential biomarker indicating the effectiveness of oxaliplatin-based treatment. The research has been published in the journal Biomedicine & Pharmacotherapy.
The Psychiatry and Mental Health Research Group at IGTP, together with the ETEP (Study and Treatment of Psychotic Episodes) group at Hospital del Mar, has published a new study analysing the prescription patterns of clozapine in patients with a first psychotic episode. This study highlights the importance of broader and earlier implementation of this treatment to improve the quality of life for patients.
DevsHealth, a leading company in artificial intelligence (AI) driven drug discovery, and the Germans Trias i Pujol Research Institute (IGTP), a public research centre in biomedical sciences, have announced a new partnership to develop new antibiotics for multi-resistant Staphylococcus aureus infections.
Cellular models used to search for new therapies for myotonic dystrophy type 1 do not usually take into account the diversity of subtypes presented by patients. A study led by researchers from IGTP has taken a step forward by developing three new models that represent this heterogeneity. The results have been published in the journal iScience.
